Danish Biotech Stock News

Novo Nordisk (CPSE:NOVO B) shares have seen subtle movement recently, and investors may be wondering how this fits into the broader trends seen across the pharmaceutical sector. Over the last month, the stock is slightly down. See our latest analysis for Novo Nordisk. Novo Nordisk’s slide over the past month reflects a sharp change in sentiment, with a 30-day share price return of -16.8% adding to a year-to-date slump of over 50%. Still, the bigger story is a fading momentum after years of...

GN Store Nord A/S recently reported its third quarter and nine-month results for 2025, revealing sales of DKK 3,958 million and net income of DKK 73 million for the quarter, both lower than the figures from the prior year. Amidst these results, net income for the first nine months dropped to DKK 309 million from DKK 621 million, underscoring a period of reduced profitability for the company. We’ll examine how this sharp decline in earnings may reshape GN Store Nord’s longer-term investment...

TORM (CPSE:TRMD A) shares have delivered a 25% gain over the past 3 months, catching the attention of investors interested in the energy sector. The stock’s performance makes it a common conversation starter for those tracking Nordic shipping companies. See our latest analysis for TORM. TORM’s recent 24.7% share price return over the last 90 days stands out against an otherwise steady year, suggesting that momentum may be building again after a relatively muted period. While the 12-month...

Hove A/S ( CPH:HOVE ) shares have continued their recent momentum with a 26% gain in the last month alone. The last 30...

ChemoMetec (CPSE:CHEMM) has caught the attention of investors recently, with shares moving higher over the past month and up nearly 40% this year. The company has seen steady annual revenue and net income growth, which continues to support confidence in its underlying business fundamentals. See our latest analysis for ChemoMetec. ChemoMetec’s share price has surged nearly 40% year-to-date, reflecting renewed optimism around the company’s strong earnings growth, even though shares faced a...

Novozymes (CPSE:NSIS B) shares have moved moderately over the past month, following steady revenue and net income growth in recent annual results. Investors keeping an eye on long-term trends may be reassessing the company’s valuation after these updates. See our latest analysis for Novozymes. Novozymes’ share price has climbed 3.2% over the past month and surged more than 6% in the last week, suggesting renewed investor interest amid its ongoing growth story. However, the total shareholder...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...

Bavarian Nordic (CPSE:BAVA) shares have moved modestly over the past week, with recent market activity reflecting investor reactions to shifting sentiment around the company's long-term prospects. For those tracking the stock, trends continue to offer potential insights. See our latest analysis for Bavarian Nordic. Bavarian Nordic’s share price has been under pressure, with a sharp 20.8% drop this past week adding to a broader 19.1% slide over the past month. While the volatility may be...

It's been a mediocre week for GN Store Nord A/S ( CPH:GN ) shareholders, with the stock dropping 10% to kr.102 in the...

Shareholders might have noticed that Solar A/S ( CPH:SOLAR B ) filed its quarterly result this time last week. The...

The fact that multiple Tryg A/S ( CPH:TRYG ) insiders offloaded a considerable amount of shares over the past year...

A.P. Møller - Mærsk A/S ( CPH:MAERSK B ) just released its latest third-quarter results and things are looking bullish...

Genmab (CPSE:GMAB) shares have seen movement recently, prompting investors to take a closer look at how the company’s fundamentals stack up. Performance trends and valuation may provide some interesting context for decisions ahead. See our latest analysis for Genmab. Genmab’s share price has surged 36% over the past 90 days, shaking off a recent 9.6% dip in the last month. This reflects building momentum and renewed optimism around growth prospects. The one-year total shareholder return sits...

TORM plc increased its full-year 2025 earnings guidance and declared an interim third-quarter dividend of US$0.62 per share, representing 78% of net profit, to be paid in December. This combination of a higher earnings outlook and robust dividend comes despite lower year-on-year sales and profits revealed in the company’s recent quarterly results. We'll explore how TORM's higher earnings guidance amid declining profits reframes the company's investment narrative. Uncover the next big thing...

Coloplast (CPSE:COLO B) just released its annual results, revealing a modest increase in sales but a drop in net income compared to last year. The company also announced updated guidance and a higher year-end dividend, which has caught investors' attention. See our latest analysis for Coloplast. After a year marked by mixed earnings, Coloplast’s share price has lost considerable ground, with a year-to-date return of -23% and a total shareholder return of -32% over the past 12 months. Despite...

Ambu (CPSE:AMBU B) just released its full-year and fourth-quarter results, revealing higher sales and a significant boost in profitability compared to last year. The company also announced an increased annual dividend, reflecting its stronger financial position. See our latest analysis for Ambu. While Ambu is celebrating stronger sales and a raised dividend, the market reaction has been anything but upbeat. Shares have slid over 23% in the past month and the one-year total shareholder return...

Key Insights Given the large stake in the stock by institutions, DSV's stock price might be vulnerable to their trading...

Ørsted (CPSE:ORSTED) shares have seen varied performance lately, with modest gains this week but losses over the past month and three months. Investors might be weighing the company’s fundamentals in comparison to recent market trends. See our latest analysis for Ørsted. Looking at the bigger picture, Ørsted’s share price has struggled, with short-term gains doing little to offset a year-to-date decline of 65%. Its one-year total shareholder return is down 44%. This fading momentum may signal...

Vestas Wind Systems A/S recently reported third-quarter 2025 results, posting sales of €5.34 billion and net income of €302 million, while narrowing its full-year revenue guidance to between €18.5 and €19.5 billion. This performance marked a turnaround from losses in the prior period and was accompanied by the announcement of four new wind turbine orders in Germany and the launch of a €150 million share buy-back programme. We'll examine how stronger profitability and tightened revenue...

A.P. Møller - Mærsk A/S announced third quarter 2025 results, reporting sales of US$14.21 billion and net income of US$1.05 billion, both down from the same period last year. Over the first nine months of 2025, sales held relatively steady year-on-year, but net income and earnings per share fell markedly, highlighting ongoing pressures on profitability. We’ll examine how the recent earnings decline could impact Maersk’s longer-term outlook, especially amid challenging global freight market...

Vestjysk Bank (CPSE:VJBA) has caught some interest recently, particularly following a surge in its stock performance over the past month. Investors appear to be watching how this Danish lender’s valuation compares after experiencing such momentum. See our latest analysis for Vestjysk Bank. The recent 37.4% jump in Vestjysk Bank’s share price over the past month has put the spotlight on both its underlying momentum and investor confidence. Looking at the bigger picture, its 1-year total...

Coloplast recently reported earnings for the fourth quarter and full year ended September 30, 2025, with annual sales rising to DKK 27.87 billion but net income falling to DKK 3.64 billion compared to the prior year; in addition, the Board recommended a year-end dividend of DKK 18 per share, bringing the full-year dividend to DKK 23 per share, up from DKK 22 last year. Alongside a modest dividend increase, the company issued new earnings guidance targeting around 7% organic revenue and EBIT...

Sydbank (CPSE:SYDB) shares have been drawing attention after recent market moves. Investors are weighing the Danish lender’s steady returns and evaluating how its performance might compare with broader trends in the banking sector. See our latest analysis for Sydbank. Sydbank’s share price has cooled slightly after a strong run, with a 2.5% dip over the last day. This is offset by a 41% year-to-date rally. The long-term story is even brighter, as the total shareholder return tops 63% over the...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...